SOUTH SAN FRANCISCO, Calif., July 23, 2018 /PRNewswire-PRWeb/ -- On June 13, 2018, GigaMune
GigaMune Inc. is a new cancer cell therapy company focused on T cell receptor (TCR) discovery and development. GigaMune was founded in 2017 as a spin-out from GigaGen, which is focused on discovery and development of therapeutic polyclonal and monoclonal antibodies. GigaMune's patented TCR technologies are an extension of GigaGen's industry-leading single cell immune repertoire technologies for antibody discovery. GigaMune's laboratory is located in South San Francisco, California.
SOURCE GigaMune Inc.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All